Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 111

1.

Realizing better doctor-patient dialogue about choices in palliative care and early phase clinical trial participation: towards an online value clarification tool (OnVaCT).

van Lent LGG, Stoel NK, van Weert JCM, van Gurp J, de Jonge MJA, Lolkema MP, Gort EH, Pulleman SM, Oomen-de Hoop E, Hasselaar J, van der Rijt CCD.

BMC Palliat Care. 2019 Nov 29;18(1):106. doi: 10.1186/s12904-019-0486-6.

2.

Phase I study of continuous olaparib capsule dosing in combination with carboplatin and/or paclitaxel (Part 1).

van der Noll R, Jager A, Ang JE, Marchetti S, Mergui-Roelvink MWJ, Lolkema MP, de Jonge MJA, van der Biessen DA, Brunetto AT, Arkenau HT, Tchakov I, Beijnen JH, de Bono JS, Schellens JHM.

Invest New Drugs. 2019 Oct 30. doi: 10.1007/s10637-019-00856-7. [Epub ahead of print]

PMID:
31667659
3.

Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2).

van der Noll R, Jager A, Ang JE, Marchetti S, Mergui-Roelvink MWJ, de Bono JS, Lolkema MP, de Jonge MJA, van der Biessen DA, Brunetto AT, Arkenau HT, Tchakov I, Beijnen JH, De Grève J, Schellens JHM.

Invest New Drugs. 2019 Oct 21. doi: 10.1007/s10637-019-00857-6. [Epub ahead of print]

PMID:
31637669
4.

The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs.

van der Velden DL, Hoes LR, van der Wijngaart H, van Berge Henegouwen JM, van Werkhoven E, Roepman P, Schilsky RL, de Leng WWJ, Huitema ADR, Nuijen B, Nederlof PM, van Herpen CML, de Groot DJA, Devriese LA, Hoeben A, de Jonge MJA, Chalabi M, Smit EF, de Langen AJ, Mehra N, Labots M, Kapiteijn E, Sleijfer S, Cuppen E, Verheul HMW, Gelderblom H, Voest EE.

Nature. 2019 Oct;574(7776):127-131. doi: 10.1038/s41586-019-1600-x. Epub 2019 Sep 30.

PMID:
31570881
5.

Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies.

de Jonge MJA, Steeghs N, Lolkema MP, Hotte SJ, Hirte HW, van der Biessen DAJ, Abdul Razak AR, De Vos FYFL, Verheijen RB, Schnell D, Pronk LC, Jansen M, Siu LL.

Target Oncol. 2019 Feb;14(1):43-55. doi: 10.1007/s11523-018-00617-1.

6.

Randomized, Open-Label, Crossover Studies Evaluating the Effect of Food and Liquid Formulation on the Pharmacokinetics of the Novel Focal Adhesion Kinase (FAK) Inhibitor BI 853520.

Verheijen RB, van der Biessen DAJ, Hotte SJ, Siu LL, Spreafico A, de Jonge MJA, Pronk LC, De Vos FYFL, Schnell D, Hirte HW, Steeghs N, Lolkema MP.

Target Oncol. 2019 Feb;14(1):67-74. doi: 10.1007/s11523-018-00618-0.

7.

53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer.

Hurley RM, Wahner Hendrickson AE, Visscher DW, Ansell P, Harrell MI, Wagner JM, Negron V, Goergen KM, Maurer MJ, Oberg AL, Meng XW, Flatten KS, De Jonge MJA, Van Herpen CD, Gietema JA, Koornstra RHT, Jager A, den Hollander MW, Dudley M, Shepherd SP, Swisher EM, Kaufmann SH.

Gynecol Oncol. 2019 Apr;153(1):127-134. doi: 10.1016/j.ygyno.2019.01.015. Epub 2019 Jan 25.

PMID:
30686551
8.

Self-reported quality of life and hope in phase-I trial participants: An observational prospective cohort study.

van der Biessen DA, Oldenmenger WH, van der Helm PG, Klein D, Oomen-de Hoop E, Mathijssen RH, Lolkema MP, de Jonge MJ.

Eur J Cancer Care (Engl). 2018 Nov;27(6):e12908. doi: 10.1111/ecc.12908. Epub 2018 Sep 4.

PMID:
30179287
9.

A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer.

van der Biessen DAJ, Gietema JA, de Jonge MJA, Desar IME, den Hollander MW, Dudley M, Dunbar M, Hetman R, Serpenti C, Xiong H, Mittapalli RK, Timms KM, Ansell P, Ratajczak CK, Shepherd SP, van Herpen CML.

Invest New Drugs. 2018 Oct;36(5):828-835. doi: 10.1007/s10637-017-0551-z. Epub 2018 Jan 8.

10.

Predicting clinical benefit from everolimus in patients with advanced solid tumors, the CPCT-03 study.

Weeber F, Cirkel GA, Hoogstraat M, Bins S, Gadellaa-van Hooijdonk CGM, Ooft S, van Werkhoven E, Willems SM, van Stralen M, Veldhuis WB, Besselink NJM, Horlings HM, Steeghs N, de Jonge MJ, Langenberg MHG, Wessels LFA, Cuppen EPJG, Schellens JH, Sleijfer S, Lolkema MP, Voest EE.

Oncotarget. 2017 Mar 8;8(33):55582-55592. doi: 10.18632/oncotarget.16029. eCollection 2017 Aug 15.

11.

Development of an item bank to measure factual disease and treatment related knowledge of rheumatoid arthritis patients in the treat to target era.

de Jonge MJ, Oude Voshaar MAH, Huis AMP, van de Laar MAFJ, Hulscher MEJL, van Riel PLCM.

Patient Educ Couns. 2018 Jan;101(1):67-73. doi: 10.1016/j.pec.2017.07.019. Epub 2017 Jul 21.

PMID:
28811047
12.

Understanding how coping strategies and quality of life maintain hope in patients deliberating phase I trial participation.

van der Biessen DA, van der Helm PG, Klein D, van der Burg S, Mathijssen RH, Lolkema MP, de Jonge MJ.

Psychooncology. 2018 Jan;27(1):163-170. doi: 10.1002/pon.4487. Epub 2017 Jul 26.

PMID:
28665008
13.

Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity.

Meulendijks D, Jacob W, Voest EE, Mau-Sorensen M, Martinez-Garcia M, Taus A, Fleitas T, Cervantes A, Lolkema MP, Langenberg MHG, De Jonge MJ, Sleijfer S, Han JY, Calles A, Felip E, Kim SW, Schellens JHM, Wilson S, Thomas M, Ceppi M, Meneses-Lorente G, James I, Vega-Harring S, Dua R, Nguyen M, Steiner L, Adessi C, Michielin F, Bossenmaier B, Weisser M, Lassen UN.

Clin Cancer Res. 2017 Sep 15;23(18):5406-5415. doi: 10.1158/1078-0432.CCR-17-0812. Epub 2017 Jun 9.

14.

A phase I pharmacokinetic and safety study of cabazitaxel in adult cancer patients with normal and impaired renal function.

Azaro A, Rodón J, Machiels JP, Rottey S, Damian S, Baird R, Garcia-Corbacho J, Mathijssen RHJ, Clot PF, Wack C, Shen L, de Jonge MJA.

Cancer Chemother Pharmacol. 2016 Dec;78(6):1185-1197. doi: 10.1007/s00280-016-3175-7. Epub 2016 Oct 27.

15.

Implementation of a Multicenter Biobanking Collaboration for Next-Generation Sequencing-Based Biomarker Discovery Based on Fresh Frozen Pretreatment Tumor Tissue Biopsies.

Bins S, Cirkel GA, Gadellaa-Van Hooijdonk CG, Weeber F, Numan IJ, Bruggink AH, van Diest PJ, Willems SM, Veldhuis WB, van den Heuvel MM, de Knegt RJ, Koudijs MJ, van Werkhoven E, Mathijssen RH, Cuppen E, Sleijfer S, Schellens JH, Voest EE, Langenberg MH, de Jonge MJ, Steeghs N, Lolkema MP.

Oncologist. 2017 Jan;22(1):33-40. doi: 10.1634/theoncologist.2016-0085. Epub 2016 Sep 23.

16.

Systematic review of patient-reported outcome measures (PROMs) for assessing disease activity in rheumatoid arthritis.

Hendrikx J, de Jonge MJ, Fransen J, Kievit W, van Riel PL.

RMD Open. 2016 Aug 18;2(2):e000202. doi: 10.1136/rmdopen-2015-000202. eCollection 2016.

17.

TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma.

Jung J, Lee JS, Dickson MA, Schwartz GK, Le Cesne A, Varga A, Bahleda R, Wagner AJ, Choy E, de Jonge MJ, Light M, Rowley S, Macé S, Watters J.

Nat Commun. 2016 Aug 31;7:12609. doi: 10.1038/ncomms12609.

18.

The time to progression ratio: a new individualized volumetric parameter for the early detection of clinical benefit of targeted therapies.

Cirkel GA, Weeber F, Bins S, Gadellaa-van Hooijdonk CG, van Werkhoven E, Willems SM, van Stralen M, Veldhuis WB, Ubink I, Steeghs N, de Jonge MJ, Langenberg MH, Schellens JH, Sleijfer S, Lolkema MP, Voest EE.

Ann Oncol. 2016 Aug;27(8):1638-43. doi: 10.1093/annonc/mdw223. Epub 2016 May 27.

19.

First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors.

Meulendijks D, Jacob W, Martinez-Garcia M, Taus A, Lolkema MP, Voest EE, Langenberg MH, Fleitas Kanonnikoff T, Cervantes A, De Jonge MJ, Sleijfer S, Soerensen MM, Thomas M, Ceppi M, Meneses-Lorente G, James I, Adessi C, Michielin F, Abiraj K, Bossenmaier B, Schellens JH, Weisser M, Lassen UN.

Clin Cancer Res. 2016 Feb 15;22(4):877-85. doi: 10.1158/1078-0432.CCR-15-1683. Epub 2015 Oct 13.

20.

The c-Met Tyrosine Kinase Inhibitor JNJ-38877605 Causes Renal Toxicity through Species-Specific Insoluble Metabolite Formation.

Lolkema MP, Bohets HH, Arkenau HT, Lampo A, Barale E, de Jonge MJA, van Doorn L, Hellemans P, de Bono JS, Eskens FALM.

Clin Cancer Res. 2015 May 15;21(10):2297-2304. doi: 10.1158/1078-0432.CCR-14-3258. Epub 2015 Mar 5.

21.

Impact of pazopanib on docetaxel exposure: results of a phase I combination study with two different docetaxel schedules.

Hamberg P, Mathijssen RH, de Bruijn P, Leonowens C, van der Biessen D, Eskens FA, Sleijfer S, Verweij J, de Jonge MJ.

Cancer Chemother Pharmacol. 2015 Feb;75(2):365-71. doi: 10.1007/s00280-014-2655-x. Epub 2014 Dec 23.

PMID:
25533184
22.
23.

Phase I study of RGB-286638, a novel, multitargeted cyclin-dependent kinase inhibitor in patients with solid tumors.

van der Biessen DA, Burger H, de Bruijn P, Lamers CH, Naus N, Loferer H, Wiemer EA, Mathijssen RH, de Jonge MJ.

Clin Cancer Res. 2014 Sep 15;20(18):4776-83. doi: 10.1158/1078-0432.CCR-14-0325. Epub 2014 Jul 14.

24.

Ecthyma gangrenosum caused by Pseudomonas aeruginosa in a patient with astrocytoma treated with chemotherapy.

De Vos FY, Middelburg TA, Seynaeve C, de Jonge MJ.

Kansenshogaku Zasshi. 2014 May;88(3 Suppl 9-10):37-9.

PMID:
24979953
25.

Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours.

Lankheet NA, Kloth JS, Gadellaa-van Hooijdonk CG, Cirkel GA, Mathijssen RH, Lolkema MP, Schellens JH, Voest EE, Sleijfer S, de Jonge MJ, Haanen JB, Beijnen JH, Huitema AD, Steeghs N.

Br J Cancer. 2014 May 13;110(10):2441-9. doi: 10.1038/bjc.2014.194. Epub 2014 Apr 15.

26.

Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.

Rodon J, Braña I, Siu LL, De Jonge MJ, Homji N, Mills D, Di Tomaso E, Sarr C, Trandafir L, Massacesi C, Eskens F, Bendell JC.

Invest New Drugs. 2014 Aug;32(4):670-81. doi: 10.1007/s10637-014-0082-9. Epub 2014 Mar 21.

PMID:
24652201
27.

Phase I pharmacokinetic and pharmacodynamic study of the first-in-class spliceosome inhibitor E7107 in patients with advanced solid tumors.

Eskens FA, Ramos FJ, Burger H, O'Brien JP, Piera A, de Jonge MJ, Mizui Y, Wiemer EA, Carreras MJ, Baselga J, Tabernero J.

Clin Cancer Res. 2013 Nov 15;19(22):6296-304. doi: 10.1158/1078-0432.CCR-13-0485. Epub 2013 Aug 27.

28.

Evaluation of patient enrollment in oncology phase I clinical trials.

van der Biessen DA, Cranendonk MA, Schiavon G, van der Holt B, Wiemer EA, Eskens FA, Verweij J, de Jonge MJ, Mathijssen RH.

Oncologist. 2013;18(3):323-9. doi: 10.1634/theoncologist.2012-0334. Epub 2013 Feb 21.

29.

Pharmacokinetics and tolerability of cediranib, a potent VEGF signalling inhibitor, in cancer patients with hepatic impairment.

van Herpen CM, Lassen U, Desar IM, Brown KH, Marotti M, de Jonge MJ.

Anticancer Drugs. 2013 Feb;24(2):204-11. doi: 10.1097/CAD.0b013e32835bd1d2.

PMID:
23197081
30.

Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors.

de Jonge MJ, Hamberg P, Verweij J, Savage S, Suttle AB, Hodge J, Arumugham T, Pandite LN, Hurwitz HI.

Invest New Drugs. 2013 Jun;31(3):751-9. doi: 10.1007/s10637-012-9885-8. Epub 2012 Oct 6.

PMID:
23054212
31.

Topical psoralen plus UV-A therapy for tyrosine kinase inhibitor-induced hand-foot syndrome.

Bos WE, Nijsten TE, de Jonge MJ, Hamberg AP.

Arch Dermatol. 2012 Apr;148(4):546-7. doi: 10.1001/archdermatol.2011.3482. No abstract available.

PMID:
22508887
32.

Danusertib, an aurora kinase inhibitor.

Meulenbeld HJ, Mathijssen RH, Verweij J, de Wit R, de Jonge MJ.

Expert Opin Investig Drugs. 2012 Mar;21(3):383-93. doi: 10.1517/13543784.2012.652303. Epub 2012 Jan 13. Review.

PMID:
22242557
33.

Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors.

Eskens FA, de Jonge MJ, Bhargava P, Isoe T, Cotreau MM, Esteves B, Hayashi K, Burger H, Thomeer M, van Doorn L, Verweij J.

Clin Cancer Res. 2011 Nov 15;17(22):7156-63. doi: 10.1158/1078-0432.CCR-11-0411. Epub 2011 Oct 5.

34.

Erlotinib 'dosing-to-rash': a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer.

Mita AC, Papadopoulos K, de Jonge MJ, Schwartz G, Verweij J, Mita MM, Ricart A, Chu QS, Tolcher AW, Wood L, McCarthy S, Hamilton M, Iwata K, Wacker B, Witt K, Rowinsky EK.

Br J Cancer. 2011 Sep 27;105(7):938-44. doi: 10.1038/bjc.2011.332. Epub 2011 Aug 30.

35.

Phase I safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumours.

de Jonge MJ, Dumez H, Kitzen JJ, Beuselinck B, Verweij J, Courtney R, Battista A, Brega N, Schöffski P.

Eur J Cancer. 2011 Jun;47(9):1328-35. doi: 10.1016/j.ejca.2011.02.012. Epub 2011 Mar 23.

36.

Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours.

Konings IR, de Jonge MJ, Burger H, van der Gaast A, van Beijsterveldt LE, Winkler H, Verweij J, Yuan Z, Hellemans P, Eskens FA.

Br J Cancer. 2010 Sep 28;103(7):987-92. doi: 10.1038/sj.bjc.6605867. Epub 2010 Sep 7.

37.

Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulation.

de Jonge MJ, Slingerland M, Loos WJ, Wiemer EA, Burger H, Mathijssen RH, Kroep JR, den Hollander MA, van der Biessen D, Lam MH, Verweij J, Gelderblom H.

Eur J Cancer. 2010 Nov;46(16):3016-21. doi: 10.1016/j.ejca.2010.07.015. Epub 2010 Aug 26.

PMID:
20801016
38.

Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib.

Steeghs N, Mathijssen RH, Wessels JA, de Graan AJ, van der Straaten T, Mariani M, Laffranchi B, Comis S, de Jonge MJ, Gelderblom H, Guchelaar HJ.

Invest New Drugs. 2011 Oct;29(5):953-62. doi: 10.1007/s10637-010-9405-7. Epub 2010 Feb 25.

39.

Ecthyma gangrenosum caused by Pseudomonas aeruginosa in a patient with astrocytoma treated with chemotherapy.

De Vos FY, Middelburg TA, Seynaeve C, de Jonge MJ.

J Infect Chemother. 2010 Feb;16(1):59-61. doi: 10.1007/s10156-009-0017-0.

PMID:
20054603
40.

Mild to moderate liver dysfunction does not require dose reduction of oral or intravenous vinorelbine: results of a pharmacokinetic study.

Kitzen JJ, Puozzo C, de Jonge MJ, Brandely M, Verweij J.

Eur J Cancer. 2010 Jan;46(2):266-9. doi: 10.1016/j.ejca.2009.10.031. Epub 2009 Nov 26.

PMID:
19944596
41.

Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors.

Steeghs N, Eskens FA, Gelderblom H, Verweij J, Nortier JW, Ouwerkerk J, van Noort C, Mariani M, Spinelli R, Carpinelli P, Laffranchi B, de Jonge MJ.

J Clin Oncol. 2009 Oct 20;27(30):5094-101. doi: 10.1200/JCO.2008.21.6655. Epub 2009 Sep 21.

PMID:
19770380
42.

Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.

Eskens FA, Steeghs N, Verweij J, Bloem JL, Christensen O, van Doorn L, Ouwerkerk J, de Jonge MJ, Nortier JW, Kraetzschmar J, Rajagopalan P, Gelderblom H.

J Clin Oncol. 2009 Sep 1;27(25):4169-76. doi: 10.1200/JCO.2008.18.8193. Epub 2009 Jul 27.

PMID:
19636022
43.

Validated bioanalytical method for the quantification of RGB-286638, a novel multi-targeted protein kinase inhibitor, in human plasma and urine by liquid chromatography/tandem triple-quadrupole mass spectrometry.

de Bruijn P, Moghaddam-Helmantel IM, de Jonge MJ, Meyer T, Lam MH, Verweij J, Wiemer EA, Loos WJ.

J Pharm Biomed Anal. 2009 Dec 5;50(5):977-82. doi: 10.1016/j.jpba.2009.06.048. Epub 2009 Jul 7.

PMID:
19628352
44.

Aurora kinase inhibitors.

Kitzen JJ, de Jonge MJ, Verweij J.

Crit Rev Oncol Hematol. 2010 Feb;73(2):99-110. doi: 10.1016/j.critrevonc.2009.03.009. Epub 2009 Apr 14. Review.

PMID:
19369091
45.

Phase I dose-escalation study of F60008, a novel apoptosis inducer, in patients with advanced solid tumours.

Kitzen JJ, de Jonge MJ, Lamers CH, Eskens FA, van der Biessen D, van Doorn L, Ter Steeg J, Brandely M, Puozzo Ch, Verweij J.

Eur J Cancer. 2009 Jul;45(10):1764-72. doi: 10.1016/j.ejca.2009.01.026. Epub 2009 Feb 27.

PMID:
19251409
46.

Irinotecan and cisplatin with concurrent thoracic radiotherapy in a once-every-three-weeks schedule in patients with limited-disease small-cell lung cancer: a phase I study.

de Jong WK, de Jonge MJ, van der Leest AH, van Meerbeeck JP, Groen HJ.

Lung Cancer. 2008 Jul;61(1):123-8. doi: 10.1016/j.lungcan.2007.11.010. Epub 2008 Jan 7.

PMID:
18179842
47.

Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia.

van der Bol JM, Mathijssen RH, Loos WJ, Friberg LE, van Schaik RH, de Jonge MJ, Planting AS, Verweij J, Sparreboom A, de Jong FA.

J Clin Oncol. 2007 Jul 1;25(19):2719-26. Epub 2007 Jun 11.

PMID:
17563393
48.

A multicentre phase I and pharmacokinetic study of BN80915 (diflomotecan) administered daily as a 20-min intravenous infusion for 5 days every 3 weeks to patients with advanced solid tumours.

Scott L, Soepenberg O, Verweij J, de Jonge MJ, Th Planting AS, McGovern D, Principe P, Obach R, Twelves C.

Ann Oncol. 2007 Mar;18(3):569-75.

49.

Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study.

de Jong FA, Kehrer DF, Mathijssen RH, Creemers GJ, de Bruijn P, van Schaik RH, Planting AS, van der Gaast A, Eskens FA, Janssen JT, Ruit JB, Verweij J, Sparreboom A, de Jonge MJ.

Oncologist. 2006 Sep;11(8):944-54.

50.

Phase I and pharmacokinetic study of halofuginone, an oral quinazolinone derivative in patients with advanced solid tumours.

de Jonge MJ, Dumez H, Verweij J, Yarkoni S, Snyder D, Lacombe D, Marréaud S, Yamaguchi T, Punt CJ, van Oosterom A; EORTC New Drug Development Group (NDDG).

Eur J Cancer. 2006 Aug;42(12):1768-74. Epub 2006 Jul 3.

PMID:
16815702

Supplemental Content

Loading ...
Support Center